<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04274595</url>
  </required_header>
  <id_info>
    <org_study_id>AOIGCSMerri/2018/PS-01</org_study_id>
    <nct_id>NCT04274595</nct_id>
  </id_info>
  <brief_title>Role of Reverse Transcriptase Inhibitors in the Treatment of Psoriasis</brief_title>
  <acronym>PSORTI-BIO</acronym>
  <official_title>Role of Reverse Transcriptase Inhibitors in the Treatment of Psoriasis: A Proof of Biological Concept Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that the inhibition of endogenous reverse transcriptase would:
      (1) reduce excess cytosolic DNA, stress initiating the inflammatory loop at the origin of
      psoriatic lesions, and (2) interrupt the loop and lighten lesions
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 15, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients no longer presenting S9.6:D5H6 RNA:DNA duplex</measure>
    <time_frame>Day 0</time_frame>
    <description>Biopsy screening for S9.6:D5H6 RNA:DNA duplex by immunofluorescence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients no longer presenting S9.6:D5H6 RNA:DNA duplex</measure>
    <time_frame>Day 7</time_frame>
    <description>Biopsy screening for S9.6:D5H6 RNA:DNA duplex by immunofluorescence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change in endogenous reverse transcriptase</measure>
    <time_frame>Day 0</time_frame>
    <description>µUI/mL reverse transcriptase activity tested in serum assayed using CAVIDI HS Mg-RT kit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in endogenous reverse transcriptase</measure>
    <time_frame>Day 7</time_frame>
    <description>µUI/mL reverse transcriptase activity tested in serum assayed using CAVIDI HS Mg-RT kit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in Ki67 proliferation marker expression</measure>
    <time_frame>Day 0</time_frame>
    <description>Percentage of cells positive for Ki67 marker on cutaneous immunohistochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in Ki67 proliferation marker expression</measure>
    <time_frame>Day 7</time_frame>
    <description>Percentage of cells positive for Ki67 marker on cutaneous immunohistochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in CK10 differentiation marker expression</measure>
    <time_frame>Day 0</time_frame>
    <description>Percentage of cells positive for CK10 marker on cutaneous immunohistochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in CK10 differentiation marker expression</measure>
    <time_frame>Day 7</time_frame>
    <description>Percentage of cells positive for CK10 marker on cutaneous immunohistochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in filaggrin differentiation marker expression</measure>
    <time_frame>Day 0</time_frame>
    <description>Percentage of cells positive for filaggrin marker on cutaneous immunohistochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in filaggrin differentiation marker expression</measure>
    <time_frame>Day 7</time_frame>
    <description>Percentage of cells positive for filaggrin marker on cutaneous immunohistochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in CD4 inflammation marker expression</measure>
    <time_frame>Day 0</time_frame>
    <description>Percentage of cells positive for CD4 marker on cutaneous immunohistochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in CD4 inflammation marker expression</measure>
    <time_frame>Day 7</time_frame>
    <description>Percentage of cells positive for CD4 marker on cutaneous immunohistochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in CD8 inflammation marker expression</measure>
    <time_frame>Day 0</time_frame>
    <description>Percentage of cells positive for CD8 marker on cutaneous immunohistochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in CD8 inflammation marker expression</measure>
    <time_frame>Day 7</time_frame>
    <description>Percentage of cells positive for CD8 marker on cutaneous immunohistochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in CD11c inflammation marker expression</measure>
    <time_frame>Day 0</time_frame>
    <description>Percentage of cells positive for CD11c marker on cutaneous immunohistochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in CD11c inflammation marker expression</measure>
    <time_frame>Day 7</time_frame>
    <description>Percentage of cells positive for CD11c marker on cutaneous immunohistochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average percentage change of Psoriasis Area Severity Index</measure>
    <time_frame>Day 7</time_frame>
    <description>Scale of four variables of psoriasis severity (minimum score 0 maximum score 72)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of side effects</measure>
    <time_frame>Day 7</time_frame>
    <description>Anticipated side effects = diarrhea, vomiting, nausea, dizziness or headache, feeling weak or rash</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of side effects</measure>
    <time_frame>Day 14</time_frame>
    <description>Anticipated side effects = diarrhea, vomiting, nausea, dizziness or headache, feeling weak or rash</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Psoriasis patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Generic antiretroviral</intervention_name>
    <description>200mg emtricitabine plus 245mg tenofovir diisopropyl fumarate for 7 days</description>
    <arm_group_label>Psoriasis patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient suffering from plaque psoriasis for more than a year with at least one active
             skin lesion&gt; 4 cm2 in the photo-protected area.

          -  Patient using effective contraception (IUD, adapted pill, condom, etc.)

          -  The patient must have given their free and informed consent and signed the consent
             form

          -  The patient must be a member or beneficiary of a health insurance plan

        Exclusion Criteria:

          -  Patient with another form or stage of psoriasis

          -  Patient on anti-cytokine treatment during the 6 months (180 days) before inclusion

          -  Patient under systemic treatment based on (1) corticosteroids, (2) antibiotics, (3)
             methotrexate, ciclosporin, soriatane, hydroxyurea, apremilast or (4) PUVA, (5) UVB,
             (6) vitamin D3 during the 4 weeks (28 days) before inclusion

          -  Patient on topical corticosteroid or retinoid treatment during the 2 weeks (15 days)
             before inclusion

          -  Patient with renal insufficiency; taking nephrotoxic agents (aminoglycosides, multiple
             or high doses of NSAIDs, etc.); creatinine clearance less than 50 ml / min; serum
             phosphorus below 1.0 mg / dl (0.32 mmol / l).

          -  Patient with active viral infection (HBV, HCV and HIV), or uncontrolled acute
             infection.

          -  Patient with hypersensitivity to one of the active substances or to any of the
             excipients (non-medicinal ingredients).

          -  Patient with uncontrolled coagulation disorder, history of keloid scars

          -  Patient with an allergy to local anesthetics; any condition likely to interfere at the
             time of the pre-inclusion visit, with the evaluation of the main objective such as
             eczema, psychiatric disorders

          -  Patient with uncontrolled systemic parameters The subject is participating in an
             interventional study, or is in a period of exclusion determined by a previous study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Stoebner</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Stoebner</last_name>
    <phone>04.66.68.40.43</phone>
    <email>pierre.stoebner@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Céline Girard</last_name>
      <phone>04.67.33.69.06</phone>
      <email>celine-girard@chumontpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Céline Girard</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Meunier</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Dereure</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacqueline Fabre</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anouck Mamoureux</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Stoebner</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier Laureillard</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Myriam Marque</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 16, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Retroviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

